MedicalXpress

MedicalXpress is a news website that provides timely and accurate information about the latest developments in medical research and healthcare. The site covers a wide range of topics including new treatments, studies, breakthroughs, and health trends. The articles are written in an accessible style that is easy to understand for the general public. While some articles may contain contradictions or deceptive practices, overall MedicalXpress provides reliable and valuable information about medical news.

92%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site is known for its high journalistic standards. It strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. It has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

95%

Examples:

  • The articles analyzed appear to be free of conflicts of interest and biases.

Conflicts of Interest

95%

Examples:

  • There is no evidence of any conflicts of interest in the articles analyzed.

Contradictions

85%

Examples:

  • Another study found that excessive sun exposure does not necessarily lead to skin cancer, contrary to popular belief.
  • There were a few instances where the data or results contradicted previous findings or expectations. For example, some studies found that certain medications were less likely to cause weight gain than others, which may be counterintuitive for some people.

Deceptions

85%

Examples:

  • Some articles may be misleading to readers who do not read them carefully. For example, one article claims that

Recent Articles

  • Healthy Diets with Less Sugar: Slowing Down Biological Aging

    Healthy Diets with Less Sugar: Slowing Down Biological Aging

    Broke On: Monday, 29 July 2024 A recent study links healthy diets, particularly those low in added sugar and rich in vitamins and minerals, to a slower rate of epigenetic aging. The UC San Francisco research found each gram of added sugar consumed increases epigenetic age. While some studies suggest vegan diets may also contribute to younger biological ages, it's crucial to consider the full context before drawing conclusions.
  • New Insights into Alzheimer's Disease: Reelin, Neurofibrillary Tangles, and Emerging Biomarkers

    New Insights into Alzheimer's Disease: Reelin, Neurofibrillary Tangles, and Emerging Biomarkers

    Broke On: Monday, 29 July 2024 Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. Recent research reveals its complex nature, focusing on pathological hallmarks - amyloid plaques and tau tangles. New findings suggest that maintaining adequate levels of Reelin protein might protect against amyloid plaque formation. Additionally, understanding cellular responses to neurofibrillary tangles could lead to potential therapeutic strategies. New biomarkers in cerebrospinal fluid offer hope for early detection and prediction.
  • GLP-1 Receptor Agonists Shift from Diabetes to Obesity Treatment: Implications and Trends

    GLP-1 Receptor Agonists Shift from Diabetes to Obesity Treatment: Implications and Trends

    Broke On: Tuesday, 23 July 2024 Since around 2020, GLP-1 receptor agonists (GLP-1 RAs) have seen a notable shift from treating type 2 diabetes to obesity in the US. This trend is driven by FDA approvals and the high prevalence of obesity, accounting for over 88% of new prescriptions being semaglutide. However, this shift raises concerns about potential drug shortages and disparities in access.
  • New HIV Prevention Drug Lenacapavir: Potential Price Drop to $40 per Year if Generics Allowed

    New HIV Prevention Drug Lenacapavir: Potential Price Drop to $40 per Year if Generics Allowed

    Broke On: Tuesday, 23 July 2024 New research suggests that the cost of producing Lenacapavir, a highly effective HIV prevention drug, could be as low as $40 per person a year if generic versions are allowed for manufacturing. This contrasts with its current price of over $40,000 per person a year in various countries. UNAIDS is urging Gilead Sciences to make the drug more accessible to people in developing countries and allow generic manufacturing through the UN-backed Medicines Patent Pool.
  • Childhood Home Instability Linked to Increased Depression Risk in Adulthood: Study

    Childhood Home Instability Linked to Increased Depression Risk in Adulthood: Study

    Broke On: Wednesday, 17 July 2024 A study in JAMA Psychiatry links multiple childhood moves to a 61% increased risk of depression in adulthood. Those who moved once were also more likely to develop depression. The researchers suggest that a stable home environment during childhood may protect against mental health issues, and children from income-deprived neighborhoods were 10% more likely to be diagnosed with depression.
  • New Study: Women in Their 40s Prefer to Delay Breast Cancer Screening After Decision Aid Intervention - What You Should Know

    New Study: Women in Their 40s Prefer to Delay Breast Cancer Screening After Decision Aid Intervention - What You Should Know

    Broke On: Tuesday, 16 July 2024 A study in the Annals of Internal Medicine found that some women in their 40s prefer to delay breast cancer screening after a decision aid intervention, with lower breast cancer risk. However, not all women should delay without consulting healthcare providers. Another study showed that those who wait until age 50 have lower risk based on family history, while earlier screenings have higher risks and less concern for downsides. The US Preventive Services Task Force recommends mammograms every other year for women aged 40-74, but many are unaware of the risks. Dr. Laura Esserman advocates for a personalized approach to screening through the WISDOM study.
  • Revolutionizing Alzheimer's Treatment: New Model Predicts Cognitive Decline and Identifies Effective Drugs

    Revolutionizing Alzheimer's Treatment: New Model Predicts Cognitive Decline and Identifies Effective Drugs

    Broke On: Thursday, 11 July 2024 Researchers in Amsterdam develop a model to predict cognitive decline in Alzheimer's patients, potentially revolutionizing treatment and management. The study aims to create an app for clinicians, offering hope for millions affected by the disease. Further research is needed to refine the model and ensure accuracy.
  • New Insights into the Role of AHR in Regulating T Cell CXCL13 Production and Potential Therapeutic Strategies for Systemic Lupus Erythematosus

    New Insights into the Role of AHR in Regulating T Cell CXCL13 Production and Potential Therapeutic Strategies for Systemic Lupus Erythematosus

    Broke On: Wednesday, 10 July 2024 New research reveals the role of the aryl hydrocarbon receptor (AHR) in regulating T cell production of CXCL13, a key chemoattractant for B cells in systemic lupus erythematosus (SLE). An imbalance between PD-1/ICOS CXCL13+ T cells and CD96hi IL-22+ T cells contributes to SLE pathology. Insufficient AHR activation leads to excess disease-causing T peripheral helper cells, while activating the AHR pathway or limiting interferon could potentially cure lupus.
  • Persistent Immune Cell Activity and SARS-CoV-2 RNA Traces in Organs of Individuals with Long COVID: Insights from UCSF and CellSight Technologies Studies

    Persistent Immune Cell Activity and SARS-CoV-2 RNA Traces in Organs of Individuals with Long COVID: Insights from UCSF and CellSight Technologies Studies

    Broke On: Tuesday, 09 July 2024 Researchers from the University of California, San Francisco and CellSight Technologies discovered that individuals who have recovered from COVID-19 may exhibit persistent immune cell activity and traces of SARS-CoV-2 RNA in various organs for up to two years after infection. These findings provide insight into the long-term effects of COVID-19, which can include symptoms such as brain fog, heart issues, lung problems, and gastrointestinal distress.
  • New Study Suggests GLP-1 Medications May Lower Risk of Obesity-Related Cancers

    New Study Suggests GLP-1 Medications May Lower Risk of Obesity-Related Cancers

    Broke On: Saturday, 06 July 2024 New study reveals GLP-1 medications, such as Ozempic and Wegovy, may lower risk of 10 obesity-related cancers for people with type 2 diabetes. The research found significant reductions in gallbladder, meningioma, pancreatic, hepatocellular carcinoma (liver), ovarian, colorectal cancer, multiple myeloma, esophageal cancer, and endometrial cancer risks. GLP-1 medications interact with insulin production systems and reduce inflammation and growth factors linked to obesity-related cancers.